Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9761.
-
Boardwalk REIT Q3 2026 Earnings Call TranscriptBoardwalk REIT (TSX:BEI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
-
JBT Marel Corporation Files Third Quarter 2026 Form 10-QJBT Marel Corporation has officially filed its Form 10-Q for the third quarter of 2026.
-
NETSCOUT to Participate in Upcoming Investor ConferencesNETSCOUT Systems, Inc. announced that its CFO and other executives will participate in the 7th Annual Needham Virtual Tech Week Conference.
-
Alamar Biosciences President Tod White Announces RetirementAlamar Biosciences, Inc. announced that President Tod White plans to retire at the end of 2026.
-
BofA Securities Raises Price Target on Alamar BiosciencesBofA Securities has increased its price target for Alamar Biosciences, Inc. from $31 to $35.
-
Citizens Maintains Market Outperform Rating on Red Rock Resorts, Adjusts Price TargetCitizens maintained its Market Outperform rating on Red Rock Resorts and slightly lowered its price target to $70 from $71.
-
StoneX Maintains Buy Rating on Red Rock Resorts, Lowers Price Target to $60StoneX reaffirmed its Buy rating for Red Rock Resorts but reduced its price target to $60 from $78.
-
Deutsche Bank Adjusts Red Rock Resorts Price Target to $67Deutsche Bank maintained its Buy rating on Red Rock Resorts while lowering its price target from $73 to $67.
-
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $17Wedbush maintained its Outperform rating on BioCryst Pharmaceuticals while adjusting its price target to $17 from $18.
-
BofA Securities Raises Price Target on Addus HomeCareBofA Securities increased its price target for Addus HomeCare Corporation to $131 from $125.
-
Barclays Adjusts Price Target for Addus HomeCareBarclays maintained its 'Underweight' rating on Addus HomeCare while increasing its price target from $96 to $101.
-
RBC Capital Markets Lowers Price Target on IDEAYA Biosciences to $45RBC Capital Markets adjusted its price target for IDEAYA Biosciences to $45 from $48 while maintaining an 'Outperform' rating.
-
ePlus Inc. Recognized as NetApp FY26 Partner Award WinnerePlus Inc. received multiple honors in the NetApp North America Partner Awards for fiscal year 2026, including recognition for new account acquisition and flash revenue growth.
-
Fairfax India Completes Subscription of Additional Equity Interest in IIFL Capital Services LimitedFairfax India Holdings Corporation has finalized the acquisition of an additional 11.2% equity interest in IIFL Capital Services Limited for approximately $211 million.
-
Needham Maintains Buy Rating on Navitas Semiconductor, Lowers Price TargetNeedham maintained its Buy rating on Navitas Semiconductor while adjusting its price target to $15 from $21.
-
Oppenheimer Raises Price Target on Tarsus Pharmaceuticals to $103Oppenheimer has increased its price target for Tarsus Pharmaceuticals from $100 to $103 while maintaining an Outperform rating.
-
Upstart Reports Q3 2026 Earnings and Revises Annual OutlookUpstart Holdings, Inc. reported third-quarter 2026 financial results, exceeding analyst estimates for revenue and earnings while lowering its full-year 2026 guidance due to macroeconomic headwinds.
-
Nomura Initiates Coverage of AXT, Inc. with Buy RatingNomura has initiated coverage on AXT, Inc. with a "Buy" rating and a price target of $90.
-
Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy RatingNeedham has maintained its 'Buy' rating on AtriCure, Inc. while increasing its price target for the company's shares from $64 to $70.
-
Joby Aviation Secures Additional U.S. Air Force Funding for Autonomous Flight TechnologyJoby Aviation announced that the U.S. Air Force has awarded additional funding to accelerate its autonomous flight technology, increasing the total commitment to nearly $37 million and raising the operational testing contract ceiling to $50 million.